Galit Zelinger
YOU?
Author Swipe
View article: A topical BRAF inhibitor (LUT-014) for treatment of radiodermatitis among women with breast cancer
A topical BRAF inhibitor (LUT-014) for treatment of radiodermatitis among women with breast cancer Open
Topical LU014 is tolerable and may be efficacious for grade 2 RD.
View article: Data from Reducing Skin Toxicities from EGFR Inhibitors with Topical BRAF Inhibitor Therapy
Data from Reducing Skin Toxicities from EGFR Inhibitors with Topical BRAF Inhibitor Therapy Open
Treatment of cancer with EGFR inhibitors is limited by on-target skin toxicities induced by inhibition of the MAPK pathway. BRAF inhibitors are known to paradoxically activate the MAPK downstream of EGFR, which we confirmed using human ski…
View article: Data from Reducing Skin Toxicities from EGFR Inhibitors with Topical BRAF Inhibitor Therapy
Data from Reducing Skin Toxicities from EGFR Inhibitors with Topical BRAF Inhibitor Therapy Open
Treatment of cancer with EGFR inhibitors is limited by on-target skin toxicities induced by inhibition of the MAPK pathway. BRAF inhibitors are known to paradoxically activate the MAPK downstream of EGFR, which we confirmed using human ski…
View article: Supplementary Figures from Reducing Skin Toxicities from EGFR Inhibitors with Topical BRAF Inhibitor Therapy
Supplementary Figures from Reducing Skin Toxicities from EGFR Inhibitors with Topical BRAF Inhibitor Therapy Open
Figure S1 and S2
View article: Supplementary Tables and Figure Legends from Reducing Skin Toxicities from EGFR Inhibitors with Topical BRAF Inhibitor Therapy
Supplementary Tables and Figure Legends from Reducing Skin Toxicities from EGFR Inhibitors with Topical BRAF Inhibitor Therapy Open
Supplementary Tables and Figure Legends
View article: Supplementary Tables and Figure Legends from Reducing Skin Toxicities from EGFR Inhibitors with Topical BRAF Inhibitor Therapy
Supplementary Tables and Figure Legends from Reducing Skin Toxicities from EGFR Inhibitors with Topical BRAF Inhibitor Therapy Open
Supplementary Tables and Figure Legends
View article: Supplementary Figures from Reducing Skin Toxicities from EGFR Inhibitors with Topical BRAF Inhibitor Therapy
Supplementary Figures from Reducing Skin Toxicities from EGFR Inhibitors with Topical BRAF Inhibitor Therapy Open
Figure S1 and S2
View article: Reducing Skin Toxicities from EGFR Inhibitors with Topical BRAF Inhibitor Therapy
Reducing Skin Toxicities from EGFR Inhibitors with Topical BRAF Inhibitor Therapy Open
Treatment of cancer with EGFR inhibitors is limited by on-target skin toxicities induced by inhibition of the MAPK pathway. BRAF inhibitors are known to paradoxically activate the MAPK downstream of EGFR, which we confirmed using human ski…
View article: VDA-1102 : A Novel Well-Tolerated Treatment For Actinic Keratosis
VDA-1102 : A Novel Well-Tolerated Treatment For Actinic Keratosis Open
not available. Disclosures: Study sponsored by Vidac Pharma. Copyright 2018 SKIN